We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Medical Research Council Technology and Pharmidex Announce Drug Discovery Collaboration
News

Medical Research Council Technology and Pharmidex Announce Drug Discovery Collaboration

Medical Research Council Technology and Pharmidex Announce Drug Discovery Collaboration
News

Medical Research Council Technology and Pharmidex Announce Drug Discovery Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Medical Research Council Technology and Pharmidex Announce Drug Discovery Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Medical Research Council Technology (MRCT) and Pharmidex have announced that Pharmidex will provide all in vivo ADME/PK drug discovery support to the MRCT in 2010.

Dr Andy Merritt, Associate Director of Chemistry at MRCT’s Centre for Therapeutics Discovery said, “As we rapidly progress a number of small molecule projects towards proof of concept studies we need to measure pharmaceutical company quality ADME information. By choosing Pharmidex as our supplier of pharmacokinetic and ADME studies we will not only access high quality laboratory services but also gain access to experience and knowledge in a scientific partnership that will enable us to develop efficient, timely, high quality studies to answer key aspects of our programme progressions.”

Dr Gary Manchee, global Head of Business Development at Pharmidex concludes that the advantages that Pharmidex offer as the partner of choice lay in the broad range of services available, the high quality of the data, bespoke study design options, and the expert DMPK advice that comes with the ‘Pharmidex package’. This powerful combination together with the “part of your lab” mentality at Pharmidex and the “quick and direct access” to our scientists working on client projects at all times, ensures responsive, fast and effective lead optimization for our client.
Advertisement